Back to Peptide Index

KPV

InflammationEvidence Level: researchNot FDA-approved for therapeutic applications; significant preclinical and clinical research ongoing
Peptide #27

KPV is a small peptide fragment derived from the larger α-MSH molecule, which plays an essential role in regulating inflammation, immune responses, and skin health. It is a naturally occurring tripeptide consisting of the amino acids Lysine, Proline, and Valine, recognized for its significant anti-inflammatory, immunomodulatory, and antimicrobial properties.

Alternative Names:

α-MSH fragment

Overview

KPV is a promising candidate for therapeutic interventions targeting inflammation, infection control, and immune modulation.

How It Works

KPV exerts anti-inflammatory effects by inhibiting inflammatory pathways and reducing cytokines. It has antimicrobial activity against bacteria and fungi.

Clinical Effects

Anti-inflammatory, antimicrobial, immunomodulatory, promotes wound healing, reduces scar formation, improves skin health

Therapeutic Applications

Inflammatory conditions, skin disorders, infection control

Research Studies

Clinical Trials

Limited human clinical trials with promising initial results

Preclinical Studies

Consistently demonstrated efficacy in accelerating wound closure, reducing scar formation, and improving skin integrity

Frequently Asked Questions

Is KPV legally available? Yes, for research purposes. Have human trials been conducted? Limited trials with promising results. What are potential side effects? Minimal and mild. How is KPV typically administered? Topically or subcutaneously. Can KPV be combined with other agents? Often studied in combination. Does KPV permanently resolve inflammation? Manages and reduces inflammation during administration.

Quick Information

Safety Information

Safety Profile

Long-term safety profiles and broader systemic effects require further investigation

Contraindications

Side Effects: Generally minimal and mild, mainly localized to injection or application sites Safety Profile: Long-term safety profiles and broader systemic effects require further investigation

Side Effects

Generally minimal and mild, mainly localized to injection or application sites

Research References

Brzoska, T., et al. (2008). The melanocortin system in inflammation: roles for alpha-MSH and KPV. Peptides. Singh, M., et al. (2013). KPV, a tripeptide of alpha-MSH, modulates inflammation in colitis. Journal of Pharmacology and Experimental Therapeutics. Cutuli, M., et al. (2000). Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology.

Additional Resources

View Source